Sarepta Issues Statement on Advisory Committee Outcome for Use of Eteplirsen in the Treatment of Duchenne Muscular Dystrophy
Go back to Sarepta Issues Statement on Advisory Committee Outcome for Use of Eteplirsen in the Treatment of Duchenne Muscular Dystrophy| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 17.65 +0.12 (0.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.53 | 52 Week High | $63.73 | |||
| Open | $17.82 | 52 Week Low | $8.00 | |||
| Day High | $18.18 | P/E | N/A | |||
| Day Low | $17.50 | EPS | $-5.69 | |||
| Volume | 2,354,758 | |||||
